GlassScriptPhysician profile
Milton Shaw
NPI 1346203007
$3,081.80
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $956 · 2020: $74.14 · 2021: $619 · 2022: $633 · 2023: $552 · 2024: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $867.30 | 2021-2024 | Ingrezza |
| Acadia Pharmaceuticals INC | $571.88 | 2019-2023 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $382.76 | 2019-2022 | |
| Urovant Sciences INC | $351.09 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $205.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $172.14 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $165.30 | 2019-2020 | |
| Mylan Specialty L.P. | $116.23 | 2021-2023 | Yupelri |
| Lilly USA, LLC | $87.44 | 2019-2023 | Trulicity |
| Teva Pharmaceuticals USA, INC. | $49.79 | 2023 | Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $49.55 | 2023 | Rexulti |
| Sumitomo Pharma America, INC. | $34.39 | 2023 | Gemtesa |
| Lundbeck LLC | $16.46 | 2023 | Rexulti |
| Allergan, INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milton Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.